Key Details
Price
$26.79Annual EPS
-$2.89Annual ROE
-28.35%Beta
1.63Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
NEW YORK CITY, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AKRO.
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan ® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELF TM score (serum fibrosis biomarker) –
FAQ
- What is the primary business of Akero Therapeutics?
- What is the ticker symbol for Akero Therapeutics?
- Does Akero Therapeutics pay dividends?
- What sector is Akero Therapeutics in?
- What industry is Akero Therapeutics in?
- What country is Akero Therapeutics based in?
- When did Akero Therapeutics go public?
- Is Akero Therapeutics in the S&P 500?
- Is Akero Therapeutics in the NASDAQ 100?
- Is Akero Therapeutics in the Dow Jones?
- When was Akero Therapeutics's last earnings report?
- When does Akero Therapeutics report earnings?
- Should I buy Akero Therapeutics stock now?